Astrazeneca (AZN) Notes Payables (2009 - 2026)

Astrazeneca's Notes Payables history runs 18 years deep, the most recent figure standing at -$46.0 million for Q1 2026.

• In Q1 2026, Notes Payables rose 95.15% year-over-year to -$46.0 million; the TTM figure through Mar 2026 stood at -$46.0 million (up 95.15% YoY), while the FY2025 annual figure was -$13.0 million, up 77.97% from the prior year.
• Notes Payables was -$46.0 million for Q1 2026 at Astrazeneca, down from -$13.0 million in the prior quarter.
• In the past five years, Notes Payables ranged from a high of -$13.0 million in Q4 2025 to a low of -$948.0 million in Q1 2025.
• Historically, Notes Payables has averaged -$249.8 million across 5 years, with a median of -$193.0 million in 2023.
• The sharpest annual moves came in 2025 and 2026: Notes Payables plunged 536.24% in 2025, then jumped 95.15% in 2026.
• A 5-year view of Notes Payables shows it stood at -$337.0 million in 2022, then surged by 42.73% to -$193.0 million in 2023, then soared by 69.43% to -$59.0 million in 2024, then surged by 77.97% to -$13.0 million in 2025, then tumbled by 253.85% to -$46.0 million in 2026.
• The last three Notes Payables figures came in at -$46.0 million (Q1 2026), -$13.0 million (Q4 2025), and -$63.0 million (Q3 2025), per Business Quant data.